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Aim: The aims of The Danish National Registry for Biological Therapy in Inflammatory Bowel 
Disease are to ensure that biological therapy and the clinical management of patients with inflamma-
tory bowel disease (IBD) receiving biological treatment are in accordance with the national clinical 
guidelines and, second, the database allows register-based clinical  epidemiological research.
Study population: The study population comprises all Danish patients with IBD (both children 
and adults) with ulcerative colitis, Crohn’s disease, and IBD unclassified who receive biological 
therapy. Patients will be enrolled consecutively when biological treatment is initiated.
Main variables: The variables in the database are: diagnosis, time of diagnosis, disease manifestation, 
indication for biological therapy, previous biological and nonbiological therapy, date of visit, clinical 
indices, physician’s global assessment, pregnancy and breastfeeding (women), height (children), weight, 
dosage (current biological agent), adverse events, surgery, endoscopic procedures, and radiology.
Descriptive data: Eleven clinical indicators have been selected to monitor the quality of 
biological treatment. For each indicator, a standard has been defined based on the available 
evidence. National results will be published in an annual report and local results on a quarterly 
basis. The indicators will be reported as department-specific proportions with 95% confidence 
intervals, and the national average will be provided for comparison. An estimated 1,200–1,300 
new biological therapies are initiated each year in Danish patients with IBD.
Conclusion: The database will be available for research during 2016. Data will be made avail-
able by The Danish Clinical Registries (www.rkkp.dk).
Keywords: inflammatory bowel disease, biological therapy, anti-TNF-α agents, quality indica-
tors, database
Background
The incidence of inflammatory bowel disease (IBD) is increasing worldwide including 
Denmark.1–4 During the last decades, introduction of biological therapy has changed the 
management of ulcerative colitis (UC) and Crohn’s disease (CD).5 As a consequence, 
the medication-related expenses of IBD therapy have increased substantially.6 Inter-
national and national treatment guidelines support clinicians in treatment decisions 
and rational clinical use of biological therapy and are used by health care providers to 
prioritize and regulate the costs of therapy.
Aim of The Danish National Registry for Biological 
Therapy in Inflammatory Bowel Disease
To ensure a rational use of biological drugs and adherence to national guidelines, The 
Danish National Registry for Biological Therapy in Inflammatory Bowel Disease 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
30
-N
ov
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
608
Larsen et al
(BIO-IBD) has been established in 2015. First, the aim of 
the database is to ensure that the choice of biological therapy 
and the clinical management of patients with IBD receiving 
biological treatment are in accordance with the national 
clinical guidelines7 and second, the database can be used for 
register-based clinical epidemiological research.
The database is planned to start in March 2016, and 
patients will be enrolled consecutively when biologi-
cal treatment is initiated. Based on recent data from The 
Danish National Patient Registry (NPR), we estimate that 
1,200–1,300 new biological therapies are initiated each year 
and at a given point in time 2,700–2,800 patients are treated 
with biological agents.
Study population
In Denmark (population of ∼5.5 million people), all citizens 
have free access to a tax-supported health care system, and 
biological therapy is only administered in public hospitals 
without cost to the patient.8
For all Danish hospitals, both public and private, it is 
mandatory by Danish law to report diagnosis and clinical 
procedures to NPR. The completeness of coding in NPR is 
very high as 99% of all hospital discharges and out-patient 
clinics from somatic hospitals are recorded.9 Likewise the 
completeness of diagnoses of IBD in NPR is very good. In 
one study, the validity of the IBD diagnoses in NPR was 
examined using the pathology system as a reference  standard, 
confirming that 94% of the UC and CD diagnoses were 
included in the NPR. The overall validity of diagnoses of 
CD in the NPR was 97%, and for UC 90%.10 Identification 
of patients is based on the Danish Civil Registration System 
(CRS). The CRS has registered all persons alive and living in 
Denmark since 1968, and has a very high accuracy of Danish 
citizens and migrations.11,12
The availability of these nationwide Danish registries 
makes it possible to retrieve data on almost all patients with 
IBD and treatment with biological agents. Hence, the study 
population comprises all Danish patients with IBD (both 
children and adults) with UC, CD, and IBD-unclassified 
(IBD-U) who receive biological therapy. Patients will be 
enrolled consecutively when biological treatment is initiated. 
Eligible patients with IBD are bio-naive patients (patients 
never treated with biological therapy); patients previously 
treated with biological therapy and stopped for .3 months, 
and patients already on biological therapy who, due to side 
effects or lack of effect, switch to another biological drug.
It is mandatory for the departments prescribing biological 
therapy to report these data to the BIO-IBD registry.
Quality indicators
Eleven quality indicators have been defined (Table 1). 
Choice, background, and level of evidence for the  indicators 
Table 1 Quality indicators
Quality indicator Indicator  
standard (%)
Type of 
indicator
1CD: Percentage of patients with luminal CD for whom the indication for biological therapy  
is in accordance with the national guidelines
$80 Process
2CD: Percentage of CD patients with no prior biological therapy for whom the selected first- 
line biological therapy is in accordance with the national guidelines
$80 Process
3CD: Percentage of patients with CD in maintenance therapy with a biological agent, who have a  
minimum of two outpatient visits per year
$80 Process
4CD: Percentage of patients in maintenance therapy with a biological agent, diagnosed with  
luminal CD, never having undergone surgery for CD, who have well-controlled disease  
(HBi score ,5 or abrPCDAi ,10)
$60 Outcome
5UC: Percentage of patients with UC for whom the indication for biological therapy is in  
accordance with the national guidelines
$80 Process
6UC: Percentage of UC patients with no prior biological therapy and chronic active disease  
for whom the selected first-line biological therapy is in accordance with the national guidelines
$80 Process
7iBD: Percentage of UC patients with acute severe ulcerative colitis for whom the selected  
first-line biological therapy is in accordance with the national guidelines
$80 Process
8UC: Percentage of patients with UC in maintenance therapy with a biological agent, who have a  
minimum of two outpatient visits per year
$80 Process
9UC: Percentage of patients with UC in maintenance therapy with a biological agent, who have  
well-controlled disease (SCCAi ,5 or PUCAi ,10)
$60 Outcome
10iBD: Percentage of patients with UC or CD, who are in steroid free remission after at least  
6 months of biological therapy
$40 Outcome
11iBD: Percentage of children with UC or CD in maintenance therapy with a biological agent,  
for whom data on height and weight is recorded in minimum two outpatient visits per year
$60 Process
Abbreviations: abrPCDAI, Abbreviated Pediatric Crohn’s Disease Activity Index; CD, Crohn’s disease; HBI, Harvey–Bradshaw Index; IBD, inflammatory bowel disease; 
PUCAi, Pediatric Ulcerative Colitis index; SCCAi, Simple Clinical Colitis Activity index; UC, ulcerative colitis.
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are described in The BIO-IBD Documentarist Report.13 
 Indicators related to outcome represent clinically relevant 
measures, with indicator standards determined from existing 
literature. Indicators related to process are addressing guide-
line adherence and administrative issues, with indicator stan-
dards determined from consensus in the working group.
In the future, new quality indicators are to be defined and 
added to the registry.
Main variables
The variables in the database are obtained by two methods: 
Data from NPR are used for registration of the IBD patient 
and basic information on diagnosis, use of biologic agent, and 
IBD-related procedures. This is supplemented with clinical 
information reported by the clinician using a national web-
based input module (Supplementary materials 1, 2, and 3). 
This is believed to ensure the best possible data quality.
1. Data harvested from NPR: diagnosis, previous biologi-
cal therapy, surgery, endoscopic procedures, radiology, 
treatment dates regarding current biological therapy, and 
current biological agent (Table 2).
2. Data reported by the clinician include: background 
information (diagnosis, time of diagnosis, disease mani-
festation, indication for biological therapy, and previous 
nonbiological therapy) and contact data at outpatient visit 
(date of the visit, relevant clinical indices [see later], 
physician’s global assessment, pregnancy/ breastfeeding 
[women], height [children], weight, dosage [current 
biological agent], nonbiological therapy, adverse events 
with regard to the biological agent, and treatment deci-
sion on continuing, changing, or stopping the biological 
agent).
3. The clinical indices used in the database are:
•	 Harvey–Bradshaw Index for CD14
•	 Abbreviated Pediatric Crohn’s Disease Activity Index 
for children with CD15
•	 Simple Clinical Colitis Activity Index for UC and 
IBD-U16
Start of a new biological
treatment course/
switch of biological treatment
Switch of
biological
treatment
- form
Discontinuation
of biological
treatment
- form
Start of 
biological
treatment course
- form
Check-up -form
Check-up -form
Check-up -form
Basic patient
information
- form
Figure 1 Patient flow in the database.
Notes: Patients will be included at start or switch of biological therapy. A form for basic patient information, start of biological therapy, outpatient visit where biological 
therapy will be administered, switch of therapy, and discontinuation of biological therapy will be available at relevant time-point in course of therapy.
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•	 Pediatric Ulcerative Colitis Activity Index for children 
with UC and IBD-U17
•	 Short Health Scale.18,19
A complete list of the variables can be found in Supple-
mentary material 2.
Data recording
The clinician is required to ensure that every eligible patient 
is entered into the database upon start of biological therapy. 
It is recommended that data are entered in the database 
every time biological treatment is administered, but as a 
minimum twice yearly and every time changes in therapy, or 
side-effects occur or if therapy is stopped. In addition to this, 
there is a continuous data collection from the NPR, which 
will ensure that all eligible patients are registered, should 
the clinician fail to include the patient at the first visit. To 
ensure the completeness of the database, the departments 
involved in administering biological treatment will receive 
lists of patients with records of biological treatment codes 
from the NPR.
The quality of data in the database relies entirely on the 
clinician/IBD nurse and is the responsibility of the depart-
ment giving biological treatment. It will only be possible to 
calculate the quality indicators if sufficient data is reported 
in the database. If it is not possible to calculate the  indicators, 
the departments with incomplete data will be mentioned 
in the annual report. There is no official quality control but as 
the results are a public document and reported on a quarterly 
basis to the departments to regularly review their clinical 
performance, it is believed to motivate the clinicians to high 
quality in both treatment and reporting.
Examples of research
The database will be available for research during 2016. Data 
will be made available by The Danish Clinical Registries 
(RKKP; www.rkkp.dk).
Administrative issues and funding
The database is administered by a steering committee, which 
comprises:
•	 Five members of the Danish Society of Gastroenterology 
and Hepatology (one member from each of the five regions 
in Denmark)
•	 A pediatric gastroenterologist, member of the Danish 
Pediatric Society
•	 A documentarist (clinician to compose a report on the 
background and evidence for the indicators)
Table 2 Codes from The Danish National Patient Registry to be 
included in the Danish Registry for Biological Therapy: iCD-10 
diagnostic codes used to identify patients with iBD
Crohn’s disease K50.0–50.9
Ulcerative colitis K51.0–51.9
IBD unclassified K51.9, K52.9
Specific drug coding: ATC-coding used with 
procedures:
BOHJ18A1 Infliximab L04AA12 or L04AB02
BOHJ18A3 Adalimumab L04AA17 or L04AB04
BOHJ18A4 Golimumab L04AB06
BOHJ18A5 Certolizumab pegol L04AB05
BOHJ26 Natalizumab L04AA23
BOHJ19H4 vedolizumab L04AA33
Operation codes
KJFB00 Small bowel resection
KJFB01 Laparoscopic small bowel resection
KJFB20 ileocecal resection
KJFB21 Laparoscopic ileocecal resection
KJFB30 Right side hemicolectomy
KJFB31 Laparoscopic right side hemicolectomy
KJFB33 Other resection of small bowel or colon
KJFB34 Other laparoscopic resection of small bowel or 
colon
KJFB40 Resection of transverse colon
KJFB41 Laparoscopic resection of transverse colon
KJFB43 Left side hemicolectomy
KJFB44 Laparoscopic left side hemicolectomy
KJFB46 Resection of sigmoid colon
KJFB47 Laparoscopic resection sigmoid colon
KJFB50 Other resection of colon
KJFB51 Other laparoscopic resection of colon
KJFB60 Resection of sigmoid colon with colostomy
KJFB61 Laparoscopic resection of sigmoid colon 
colostomy and distal closure
KJFB63 Other colon resection colostomy an distal 
closure
KJFB64 Other laparoscopic colon resection with 
colostomy and distal closure
KJFB96 Other gut resection
KJFB97 Other laparoscopic gut resection
KJFH00 Colectomy and ileorectal stoma
KJFH10 Colectomy and ileostomy
KJFH11 Laparoscopic colectomy and ileostomy
KJFH20 Proctocolectomy and ileostomy
KJFH96 Other colectomy
KJGB00 Resection of rectum
KJGB01 Laparoscopic resection of rectum with colorectal 
or coloanal anastomosis
KJGB10 Resection of rectum with colostomy
KJGB11 Laparoscopic resection of rectum with colostomy
KJGB30 Abdominoperianal resection of rectum
KJGB31 Laparoscopic and perianal excision of rectum
MRI
UXMD MRi of abdomen and pelvis
UXMD10 MRi of upper abdomen
UXMD15 MRi of lower abdomen, including pelvis
UXMD20 MRi of retroperitoneum
(Continued)
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approval is not required according to Danish law when data 
are used to monitor, secure, and improve clinical quality.
Conclusion
Based on the indicators defined, an annual report will state 
the quality of biological therapy in patients with IBD treated 
in Denmark, both at a national and department level together 
with a complete overview of the data available.
In addition, results are reported on a quarterly basis to the 
departments to regularly review their clinical performance. 
The indicators will be reported as department-specific propor-
tions with 95% confidence intervals, and the national average 
will be provided for comparison. For each indicator, a standard 
has been developed based on the available evidence.
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